In 2023, a randomised controlled trial on 338 participants showed that retatrutide supported an average weight loss of 24% after 48 weeks. If you weighed 100 kg, this would be a weight loss of 24kg.
Additionally, 100% of participants on the higher doses of the drug lost more than 5% of their weight, 93% lost more than 10%, and 15% lost more than 15%.
Strikingly, 26% of participants on the highest dose of retatrutide (12 mg) lost more than 30% of their body weight.
Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications related to obesity, including hypertension, type 2 diabetes, and heart disease.
A recent paper published in The Lancet showed that nearly 20% of participants in lifestyle interventions without medications gain weight, around 40% lose between 1-10% of their body weight, and just 13% lose more than 10%.
So, combining retatrutide with a lifestyle intervention leads to significantly greater weight loss than lifestyle interventions without medication.
